The groups treated with ruxolitinib or anti-IL4Rα in MR-treated IL-4/IL-13 represent the AD skin topically treated with ruxolitinib or anti-IL4Rα in AD-induced skin with the presence of MR. Here, IL13 is linked to Alzheimer disease.